XML 60 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Emflaza asset acquisition - Purchase consideration (Details) - USD ($)
$ in Thousands
 12 Months Ended
Apr. 20, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]        
Cash consideration   $ 77,163 $ 0 $ 0
Issuance of common stock related to acquisition   $ 75,191    
Intellectual Property | Marathon Pharmaceuticals, LLC        
Finite-Lived Intangible Assets [Line Items]        
Cash consideration $ 75,000      
Issuance of common stock related to acquisition 75,190      
Acquisition costs 2,163      
Total preliminary consideration transferred $ 152,353